Orion will publish Financial Statement Release for 2022 on Thursday, 9 February 2023. The report, related presentation material and link to webcast are available here after publishing.
|1/25/2023||154,112 Orion Corporation A shares converted into B shares|
|1/12/2023||Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2023 Annual General Meeting|
|12/28/2022||40,443 Orion Corporation A shares converted into B shares|
|11/4/2022||Orion Corporation completed share acquisitions|
Possible requests from the shareholders to have a matter dealt with by Orion Corporation’s Annual General Meeting 2023 must be submitted to the Board of Directors of Orion Corporation no later than Monday, 16 January 2023.
|1/27/2023||Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer|
|1/26/2023||Orion publishes Financial Statement Release for 2022 on Thursday 9 February 2023|
|1/4/2023||Orion and Amneal enter strategic partnership – Orion receives exclusive licence to commercialise Amneal’s generic products in Europe, Australia and New Zealand|
|10/27/2022||Orion Research Foundation is awarding EUR 1 million in grants and two EUR 100,000 special grants today|
The Annual General Meeting of Orion Corporation was held on Wednesday 23 March 2022. The decisions and related material are available here.
The latest Corporate Governance Statement of Orion Corporation is available at the archive of Corporate Governance Statements.
Orion’s virtual Capital Markets Day 2021 was held on 26 May 2021. Presentations and webcast from the event are available here.
Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.
Research and development are Orion's strengths, and the company will continue to invest in them. The target is to increase net sales 1.5-fold by 2025.